/ News, Research
A high-throughput drug screen reveals means to differentiate triple-negative breast cancer (Bentires-Alj Lab)
A study published by the Bentires-Alj Lab reveals that PLK1 inhibitors induce differentiation in triple-negative breast cancer.
One characteristic of cancer cells is their high adaptability to different environments. A study published by the Bentires-Alj Lab aimed to harness this high adaptability of cancer cells and force them to differentiate into normal cells. In collaboration with Novartis, they tested more than 9500 compounds for their efficacy in differentiating cancer cells. They revealed that inhibitors of polo-like kinase 1 (PLK1) promoted the differentiation of triple-negative breast cancer.